Drugs in phase I and phase II clinical trials for systemic sclerosis.
Melody P ChungLorinda S ChungPublished in: Expert opinion on investigational drugs (2020)
Introduction: Systemic sclerosis (SSc) is an autoimmune connective tissue disease that is characterized by excessive collagen deposition, vascular dysfunction, and fibrosis of cutaneous and visceral organs. Current therapeutic options are limited and provide only modest benefit.Areas covered: This review summarizes investigational agents in recent Phase I and II clinical trials evaluated for the treatment of SSc with a focus on skin in patients with early diffuse disease and interstitial lung disease. We performed a search on Pubmed and https://clinicaltrials.gov with keywords systemic sclerosis, Phase I clinical trial, and Phase II clinical trial to identify relevant studies from 2015 to 2019.Expert opinion: Therapeutic interventions in SSc should be guided by the level of disease activity and the degree of organ involvement. While most novel agents have failed to meet the primary endpoints of reducing skin thickening as measured by the modified Rodnan skin score, some have shown promise in improving the Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS), reducing lung function decline, or improving patient-reported outcomes. However, most of the current evidence is based on small or open-label clinical trials. Well-designed, large, randomized, Phase III clinical trials are necessary to define the roles of investigational agents in treating SSc.
Keyphrases
- systemic sclerosis
- phase ii
- clinical trial
- interstitial lung disease
- open label
- phase iii
- double blind
- lung function
- disease activity
- patient reported outcomes
- rheumatoid arthritis
- phase ii study
- placebo controlled
- wound healing
- systemic lupus erythematosus
- study protocol
- ankylosing spondylitis
- air pollution
- soft tissue
- chronic obstructive pulmonary disease
- type diabetes
- oxidative stress
- low grade
- machine learning
- drug induced
- juvenile idiopathic arthritis
- replacement therapy
- weight loss
- randomized controlled trial